Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Validation of the TWO-ROP Algorithm at a Tertiary Referral Center
Author Affiliations & Notes
  • Francisco Altamirano Lamarque
    Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, United States
  • Sandra Alhoyek
    Ophthalmology, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Efren Gonzalez
    Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, United States
  • Hanna De Bruyn
    Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, United States
  • Anne B Fulton
    Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, United States
  • Ryan Gise
    Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, United States
  • Iason M. Mantagos
    Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, United States
  • Carolyn Wu
    Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, United States
  • Deborah K. VanderVeen
    Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, United States
  • Nimesh A. Patel
    Ophthalmology, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
    Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Francisco Altamirano Lamarque None; Sandra Alhoyek None; Efren Gonzalez None; Hanna De Bruyn None; Anne Fulton None; Ryan Gise None; Iason Mantagos None; Carolyn Wu None; Deborah VanderVeen None; Nimesh Patel Regeneron, Dutch Ophthalmic, Genentech, EyePoint Pharmaceuticals, Alcon Vision, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6268. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Francisco Altamirano Lamarque, Sandra Alhoyek, Efren Gonzalez, Hanna De Bruyn, Anne B Fulton, Ryan Gise, Iason M. Mantagos, Carolyn Wu, Deborah K. VanderVeen, Nimesh A. Patel; Validation of the TWO-ROP Algorithm at a Tertiary Referral Center. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6268.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The burden of screening for retinopathy of prematurity (ROP) is challenging even in high-income countries. This study was performed to validate the TWO-ROP algorithm, which proposes limited screening for infants who do not meet both gestational age (GA) and birth weight (BW) criteria.

Methods : Retrospective study of infants screened from 2013 to 2023. We collected GA at birth, BW, age at ROP diagnosis, ROP zone and stage, presence of plus disease, and ROP treatments. Rates of ROP and treatment-warranted ROP (TW-ROP) were evaluated in group 1 (BW<1500 g, GA≥30 weeks), group 2 (BW≥1500g, GA<30 weeks), and group 3 (BW≥1500g, GA≥30 weeks). Categorical data were analyzed with Chi-square test and continuous variables were compared with analysis of variance.

Results : Of the 3,930 screened infants, 1,095 (27.9%) met the inclusion criteria. The number of patients in groups 1, 2, and 3 were 837 (76.4%), 72 (6.6%), and 186 (17.0%), respectively. ROP was detected in 106 out of 1095 (9.7%) patients; within each group, the rate was 9.1% (76 patients) in group 1, 18.1% (13 patients) in group 2, and 9.1% (17 patients) in group 3 (p=0.045). The mean corrected GA at ROP diagnosis was 37.3 weeks for group 1, 35.1 weeks for group 2, and 37.7 for group 3 (p=0.026). The mean interval between birth and ROP diagnosis was 47.3 days (range 26-108 days) in group 1, 44.2 days in group 2 (range 30-79 days), and 52.5 days (range 25-95 days) in group 3 (p=0.477). Within ROP patients, 88 (8.0%) had stage 1, and 13 (1.2%) had stage 2 in their worst eye. Stage 3 was found in 9 eyes of 5 patients (0.5%, all zone II). Three eyes of 2 patients (0.2%) had plus disease. No zone 1, stage 4, or stage 5 cases were recorded. Two patients had bilateral laser treatment at mean 40.3 weeks corrected GA; 3 out of 4 of these eyes met Type 1 treatment criteria.

Conclusions : The previously published TWO-ROP algorithm suggested that for infants meeting 0 or 1 screening criterion, a single screening exam prior to or just after discharge from the NICU could alleviate ROP examination burden while maintaining safety. Given the current validation results with two patients with TW-ROP, our recommendation is that the proposed single screen occurs prior to discharge to ensure timely diagnosis, follow-up, and treatment.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×